Suppr超能文献

抗结核治疗后全血培养中抗分枝杆菌免疫的菌株特异性。

Strain specificity of antimycobacterial immunity in whole blood culture after cure of tuberculosis.

机构信息

Pfizer Specialty Care, New London, CT 06320, USA.

出版信息

Tuberculosis (Edinb). 2009 May;89(3):221-4. doi: 10.1016/j.tube.2009.02.001. Epub 2009 Mar 24.

Abstract

Bactericidal assays have facilitated development of most modern vaccines, and have been proposed as indicators of protection after vaccination against tuberculosis. We examined control of intracellular growth of Mycobacterium tuberculosis in whole blood cultures of cured TB patients and tuberculin-negative healthy volunteers. Cured patients showed superior restriction of growth of the strain with which they had been infected. They similarly showed superior control of growth of a clinical strain (MP-28) that had become attenuated during passage. However, patients and healthy volunteers did not differ with regard to control of M. tuberculosis H37Ra. The ability of cured patients to control growth of the strain with which they had been infected correlated with MP-28, but not with H37Ra. These findings indicate M. tuberculosis MP-28 may be suitable to assess mycobacterial immunity as growth inhibition in whole blood culture, whereas H37Ra is not. However, additional studies will be required to confirm these observations in additional patient and microbial populations that are distinct according to geography and microbial and host genetics.

摘要

杀菌试验促进了大多数现代疫苗的发展,并被提议作为接种结核病疫苗后的保护指标。我们研究了已治愈的结核病患者和结核菌素阴性的健康志愿者的全血培养物中对结核分枝杆菌的细胞内生长的控制。已治愈的患者显示出对其感染的菌株生长的优越限制。他们对在传代过程中减毒的临床菌株(MP-28)的生长也表现出优越的控制。然而,患者和健康志愿者在控制结核分枝杆菌 H37Ra 方面没有差异。已治愈的患者控制其感染的菌株生长的能力与 MP-28 相关,但与 H37Ra 不相关。这些发现表明,结核分枝杆菌 MP-28 可能适合作为全血培养中的生长抑制来评估分枝杆菌免疫,而 H37Ra 则不适合。然而,需要进行更多的研究来确认这些观察结果在根据地理位置以及微生物和宿主遗传学而不同的其他患者和微生物群体中的适用性。

相似文献

1
Strain specificity of antimycobacterial immunity in whole blood culture after cure of tuberculosis.
Tuberculosis (Edinb). 2009 May;89(3):221-4. doi: 10.1016/j.tube.2009.02.001. Epub 2009 Mar 24.
2
Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis.
Clin Diagn Lab Immunol. 2002 Jul;9(4):901-7. doi: 10.1128/cdli.9.4.901-907.2002.
5
Pilot studies of a human BCG challenge model.
Tuberculosis (Edinb). 2017 Jul;105:108-112. doi: 10.1016/j.tube.2017.05.001. Epub 2017 May 4.
6
Natural and trained innate immunity against Mycobacterium tuberculosis.
Immunobiology. 2020 May;225(3):151951. doi: 10.1016/j.imbio.2020.151951. Epub 2020 Apr 27.
8
Rapid determination of growth inhibition of Mycobacterium tuberculosis by GC-MS/MS quantitation of tuberculostearic acid.
Tuberculosis (Edinb). 2013 May;93(3):322-9. doi: 10.1016/j.tube.2012.12.004. Epub 2013 Feb 28.
9
Monitoring Anti-tuberculosis Treatment Response Using Analysis of Whole Blood Specific T Cell Activation and Functional Markers.
Front Immunol. 2020 Sep 9;11:572620. doi: 10.3389/fimmu.2020.572620. eCollection 2020.

引用本文的文献

1
Development and application of the direct mycobacterial growth inhibition assay: a systematic review.
Front Immunol. 2024 Feb 6;15:1355983. doi: 10.3389/fimmu.2024.1355983. eCollection 2024.
2
Whole Blood Mycobacterial Growth Assays for Assessing Human Tuberculosis Susceptibility: A Systematic Review and Meta-Analysis.
Front Immunol. 2021 May 11;12:641082. doi: 10.3389/fimmu.2021.641082. eCollection 2021.
3
Evaluation of the Antibody in Lymphocyte Supernatant Assay to Detect Active Tuberculosis.
PLoS One. 2017 Jan 13;12(1):e0169118. doi: 10.1371/journal.pone.0169118. eCollection 2017.
5
Plasma drug activity assay for treatment optimization in tuberculosis patients.
Antimicrob Agents Chemother. 2011 Dec;55(12):5819-25. doi: 10.1128/AAC.05561-11. Epub 2011 Oct 3.
6
Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis.
Antimicrob Agents Chemother. 2011 Feb;55(2):567-74. doi: 10.1128/AAC.01179-10. Epub 2010 Nov 15.

本文引用的文献

1
Tuberculosis vaccine development: goals, immunological design, and evaluation.
Lancet. 2008 Jul 12;372(9633):164-175. doi: 10.1016/S0140-6736(08)61036-3.
3
Relationship between whole-blood interferon-gamma responses and the risk of active tuberculosis.
Tuberculosis (Edinb). 2008 May;88(3):244-8. doi: 10.1016/j.tube.2007.11.009. Epub 2008 Feb 21.
4
Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP.
PLoS Pathog. 2008 Feb 8;4(2):e33. doi: 10.1371/journal.ppat.0040033.
5
Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis.
Am J Respir Crit Care Med. 2008 May 15;177(10):1164-70. doi: 10.1164/rccm.200711-1613OC. Epub 2008 Feb 14.
6
Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis.
Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12434-9. doi: 10.1073/pnas.0703510104. Epub 2007 Jul 18.
8
Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development.
Lancet Infect Dis. 2007 May;7(5):328-37. doi: 10.1016/S1473-3099(07)70108-1.
9
Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity.
J Infect Dis. 2006 Aug 15;194(4):486-92. doi: 10.1086/505430. Epub 2006 Jul 10.
10
Survival and replication of clinical Mycobacterium tuberculosis isolates in the context of human innate immunity.
Infect Immun. 2005 May;73(5):2595-601. doi: 10.1128/IAI.73.5.2595-2601.2005.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验